Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus Anlotinib in Advanced NSCLC Post-Immunotherapy
NCT06356675Phase 4Not yet recruiting
- Start
- Jul 2024
- Primary completion
- Jul 2028
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 4 trial of tislelizumab, anlotinib in non-small cell lung cancer (NSCLC). Planned start Jul 2024; status: not yet recruiting.
02
Drugs
tislelizumabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06356675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06356675.